Patents by Inventor Bernard Monsarrat

Bernard Monsarrat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel Phosphorylated Phosphatase Cdc25b Sequences, Antibodies Directed Against Said Sequences and Uses Thereof
    Publication number: 20080219987
    Abstract: A peptide sequence includes a fragment of at least 10 amino acids derived from the following SEQ ID NO:1: DRKMEVEELSpPLALGRFSL SEQ ID NO:1 wherein the serine residue in position 10 is phosphorylated, the above-mentioned fragment containing the phosphorylated serine residue. A polyclonal or monoclonal antibody capable of identifying a peptide sequence as defined above is also disclosed.
    Type: Application
    Filed: August 23, 2005
    Publication date: September 11, 2008
    Inventors: Bernard Ducommun, Martine Cazales, Bernard Monsarrat
  • Novel Phosphorylated Sequences of the Phosphatase Cdc25B, Antibodies for Said Sequences and Use Thereof
    Publication number: 20080008712
    Abstract: The present invention relates to a peptide sequence characterized in that it comprises or is constituted by a fragment of at least approximately 10 amino acids originating from the following sequence SEQ ID NO: 1: TPVQNKRRRSpVTPPEEQQE SEQ ID NO: 1 in which the serine residue in position 10 is phosphorylated, said above-mentioned fragment containing said phosphorylated serine residue. The present invention also relates to a polyclonal or monoclonal antibody capable of recognizing a peptide sequence as defined above.
    Type: Application
    Filed: June 8, 2004
    Publication date: January 10, 2008
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE RENNES 1, UNIVERSITE PAUL SABATIER TOULOUSE III
    Inventors: Bernard Ducommun, Bernard Monsarrat, Claude Prigent
  • Structurally modified peptides that are resistant to peptidase degradation
    Patent number: 6623740
    Abstract: Human melanoma cells bear antigens that are recognized by autologous CD8+ cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by HLA molecules. Disclosed herein are peptide analogues of the tumor antigen MZ2-E that have been modified to resist peptidase degradation, and which bind HLA molecules to form a complex whose recognition by specific cytolytic T cells leads to lysis of the complex. The identification by cytolytic T cells of the peptide analogue/HLA complex may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: September 23, 2003
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean Edouard Gairin, Maha Ayyoub, Benoit Van Den Eynde, Honoré Mazarguil, Bernard Monsarrat
  • Structurally modified peptides that are resistant to peptidase degradation
    Patent number: 6087441
    Abstract: Human melanoma cells bear antigens that are recognized by autologous CD8+ cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by HLA molecules. Disclosed herein are peptide analogues of the tumor antigen MZ2-E that have been modified to resist peptidase degradation, and which bind HLA molecules to form a complex whose recognition by specific cytolytic T cells leads to lysis of the complex. The identification by cytolytic T cells of the peptide analogue/HLA complex may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: July 11, 2000
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Jean Edouard Gairin, Maha Ayyoub, Benoit Van Den Eynde, Honore Mazarguil, Bernard Monsarrat